{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:01:32Z","timestamp":1790805692955,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T00:00:00Z","timestamp":1645488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s40261-022-01119-9","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T13:02:44Z","timestamp":1645534964000},"page":"193-197","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection"],"prefix":"10.1007","volume":"42","author":[{"given":"Ira M.","family":"Leviton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4846-9284","authenticated-orcid":false,"given":"Maria","family":"Amodio-Groton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,22]]},"reference":[{"issue":"6","key":"1119_CR1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa1800201","volume":"380","author":"R Stets","year":"2019","unstructured":"Stets R, Popescu M, Gonong JR, Mitha I, Nseir W, Madej A, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1800201.","journal-title":"N Engl J Med"},{"issue":"6","key":"1119_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, Puljiz I, Metallidis S, Gardovskis J, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380(6):528\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1800170.","journal-title":"N Engl J Med"},{"issue":"10","key":"1119_CR3","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O\u2019Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, Sirbu A, Garrity-Ryan L, Das AF, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19(10):1080\u201390. https:\/\/doi.org\/10.1016\/S1473-3099(19)30275-0.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1119_CR4","doi-asserted-by":"publisher","first-page":"e02057","DOI":"10.1128\/AAC.02057-17","volume":"62","author":"JK Berg","year":"2018","unstructured":"Berg JK, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Pharmacokinetics and safety of omadacycline in subjects with impaired renal function. Antimicrob Agents Chemother. 2018;62(2):e02057-e2117. https:\/\/doi.org\/10.1128\/AAC.02057-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"1119_CR5","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1093\/cid\/ciz394","volume":"69","author":"JC Gallagher","year":"2019","unstructured":"Gallagher JC. Omadacycline: a modernized tetracycline. Clin Infect Dis. 2019;69(suppl 1):S1-5. https:\/\/doi.org\/10.1093\/cid\/ciz394.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"1119_CR6","doi-asserted-by":"publisher","first-page":"e01650","DOI":"10.1128\/AAC.01650-20","volume":"64","author":"SJ Kovacs","year":"2020","unstructured":"Kovacs SJ, Ting L, Praestgaard J, Sunkara G, Sun H, Stein DS, et al. An open-label study of the impact of hepatic impairment on the pharmacokinetics and safety of single oral and intravenous doses of omadacycline. Antimicrob Agents Chemother. 2020;64(1):e01650-e1720. https:\/\/doi.org\/10.1128\/AAC.01650-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1119_CR7","unstructured":"NUZYRA [prescribing information]. King of Prussia, PA: Paratek Pharmaceuticals, Inc. May 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/209816s011,209817s010lbl.pdf. Accessed 5 Aug 2021."},{"issue":"4","key":"1119_CR8","first-page":"168","volume":"12","author":"T Lodise","year":"2019","unstructured":"Lodise T, LaPensee K. Cost-saving opportunities with an oral and intravenous once-daily aminomethylcycline antibiotic for community-acquired bacterial pneumonia: Findings from decision-analytic models. Am Health Drug Benefits. 2019;12(4):168\u201376.","journal-title":"Am Health Drug Benefits."},{"issue":"9","key":"1119_CR9","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3390\/antibiotics9090577","volume":"9","author":"TP Lodise","year":"2020","unstructured":"Lodise TP, Van Le H, LaPensee K. Hospital admission patterns in adult patients with community-acquired pneumonia who received ceftriaxone and a macrolide by disease severity across United States hospitals. Antibiotics (Basel). 2020;9(9):577. https:\/\/doi.org\/10.3390\/antibiotics9090577.","journal-title":"Antibiotics (Basel)."},{"key":"1119_CR10","unstructured":"ClinicalTrials.gov. Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia. NCT 04160260. https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT04160260. Updated 3 November 2021. Accessed 1 Dec 2021."},{"issue":"7","key":"1119_CR11","doi-asserted-by":"publisher","first-page":"e02263","DOI":"10.1128\/AAC.02263-19","volume":"64","author":"EA Lakota","year":"2020","unstructured":"Lakota EA, Van Wart SA, Trang M, Tzanis E, Bhavnani SM, Safir MC, et al. Population pharmacokinetic analyses for omadacycline using Phase 1 and 3 data. Antimicrob Agents Chemother. 2020;64(7):e02263-e2319. https:\/\/doi.org\/10.1128\/AAC.02263-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"1119_CR12","doi-asserted-by":"publisher","first-page":"e01487","DOI":"10.1128\/AAC.01487-17","volume":"62","author":"LA Bundrant","year":"2018","unstructured":"Bundrant LA, Tzanis E, Garrity-Ryan L, Bai S, Chitra S, Manley A, et al. Safety and pharmacokinetics of the aminomethylcycline antibiotic omadacycline administered to healthy subjects in oral multiple-dose regimens. Antimicrob Agents Chemother. 2018;62(2):e01487-e1517. https:\/\/doi.org\/10.1128\/AAC.01487-17.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"1119_CR13","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1093\/cid\/ciz309","volume":"69","author":"KA Rodvold","year":"2019","unstructured":"Rodvold KA, Pai MP. Pharmacokinetics and pharmacodynamics of oral and intravenous omadacycline. Clin Infect Dis. 2019;69(suppl 1):S16-22. https:\/\/doi.org\/10.1093\/cid\/ciz309.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"1119_CR14","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1080\/00498254.2016.1213465","volume":"47","author":"J Flarakos","year":"2016","unstructured":"Flarakos J, Du Y, Gu H, Wang L, Einolf HJ, Chun DY, et al. Clinical disposition, metabolism and in vitro drug\u2013drug interaction properties of omadacycline. Xenobiotica. 2016;47(8):682\u201396. https:\/\/doi.org\/10.1080\/00498254.2016.1213465.","journal-title":"Xenobiotica"},{"issue":"12","key":"1119_CR15","doi-asserted-by":"publisher","first-page":"7432","DOI":"10.1128\/AAC.01393-16","volume":"60","author":"H Sun","year":"2016","unstructured":"Sun H, Ting L, Machineni S, Praestgaard J, Kuemmell A, Stein DS, et al. Randomized, open-label study of the pharmacokinetics and safety of oral and intravenous administration of omadacycline to healthy subjects. Antimicrob Agents Chemother. 2016;60(12):7432\u20135. https:\/\/doi.org\/10.1128\/AAC.01393-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1119_CR16","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1093\/jac\/dkaa558","volume":"76","author":"MP Pai","year":"2021","unstructured":"Pai MP, Wilcox MH, Chitra S, McGovern PC. Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections. J Antimicrob Chemother. 2021;76(5):1315\u201322. https:\/\/doi.org\/10.1093\/jac\/dkaa558.","journal-title":"J Antimicrob Chemother"},{"key":"1119_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106442","volume":"184","author":"MP Pai","year":"2021","unstructured":"Pai MP, Wilcox M, Chitra S, McGovern P. Safety and efficacy of omadacycline by body mass index in patients with community-acquired bacterial pneumonia: subanalysis from a randomized controlled trial. Respir Med. 2021;184: 106442. https:\/\/doi.org\/10.1016\/j.rmed.2021.106442.","journal-title":"Respir Med"},{"issue":"1","key":"1119_CR18","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1086\/510079","volume":"44","author":"PG Ambrose","year":"2007","unstructured":"Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, et al. Pharmacokinetics\u2013pharmacodynamics of antimicrobial therapy: it\u2019s not just for mice anymore. Clin Infect Dis. 2007;44(1):79\u201386. https:\/\/doi.org\/10.1086\/510079.","journal-title":"Clin Infect Dis"},{"key":"1119_CR19","unstructured":"Bhavnani SM, Hammel JP, Lakota EA, Bader JC, Bulik CC, VanScoy BD, et al. Pharmacokinetic-pharmacodynamic target attainment analyses evaluating omadacycline dosing regimens for the treatment of patients with community-acquired bacterial pneumonia for Streptococcus pneumoniae and Haemophilus influenzae. In: Presented at the American Society for Microbiology Annual Microbe Meeting. Atlanta, GA; June 7\u201311, 2018: Poster Sa625."},{"key":"1119_CR20","unstructured":"Bhavnani SM, Hammel JP, Lakota EA, Liolios K, Rubino CM, Steenbergen JN, et al. Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections. In: Presented at the 29th European Congress of Clinical Microbiology and Infectious Diseases. Amsterdam, Netherlands; April 13\u201316, 2019: Poster P1944."},{"key":"1119_CR21","doi-asserted-by":"crossref","unstructured":"Friedrich L, Curran M, Chitra S, Manley A, Bai S, Noble B, et al. Modeling the pharmacokinetics and pharmacodynamics of intravenous and oral omadacycline with and without a loading dose. In: Presented at IDWeek 2019. Washington, DC; October 2\u20136, 2019: Poster 734.","DOI":"10.1093\/ofid\/ofz360.802"},{"issue":"5","key":"1119_CR22","doi-asserted-by":"publisher","first-page":"e02488","DOI":"10.1128\/AAC.02488-19","volume":"64","author":"MA Pfaller","year":"2020","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the United States and Europe: report from the SENTRY Antimicrobial Surveillance Program, 2016 to 2018. Antimicrob Agents Chemother. 2020;64(5):e02488-e2519. https:\/\/doi.org\/10.1128\/AAC.02488-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"1119_CR23","doi-asserted-by":"publisher","first-page":"e02368","DOI":"10.1128\/AAC.02368-16","volume":"61","author":"AJ Lepak","year":"2017","unstructured":"Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model. Antimicrob Agents Chemother. 2017;61(5):e02368-e2416. https:\/\/doi.org\/10.1128\/AAC.02368-16.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"1119_CR24","doi-asserted-by":"publisher","first-page":"e00624","DOI":"10.1128\/AAC.00624-19","volume":"63","author":"AJ Lepak","year":"2019","unstructured":"Lepak AJ, Zhao M, Marchillo K, VanHecker J, Andes DR. In vivo pharmacodynamics of omadacycline against staphylococcus aureus in the neutropenic murine thigh infection model. Antimicrob Agents Chemother. 2019;63(7):e00624-e719.","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"1119_CR25","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/cid\/ciz398","volume":"69","author":"S Opal","year":"2019","unstructured":"Opal S, File TM Jr, van der Poll T, Tzanis E, Chitra S, McGovern PC. An integrated safety summary of omadacycline, a novel aminomethylcycline. Clin Infect Dis. 2019;69(suppl 1):S40-47. https:\/\/doi.org\/10.1093\/cid\/ciz398.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"1119_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","volume":"80","author":"GG Zhanel","year":"2020","unstructured":"Zhanel GG, Esquivel J, Zelenitsky S, Lawrence CK, Adam HJ, Golden A, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80(3):285\u2013313. https:\/\/doi.org\/10.1007\/s40265-020-01257-4.","journal-title":"Drugs"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-022-01119-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-022-01119-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T14:42:57Z","timestamp":1647528177000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-022-01119-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,22]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1007\/s40261-022-01119-9","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,22]]},"assertion":[{"value":"12 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article\u00a0was funded by Paratek Pharmaceuticals, Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"IL has no financial disclosures. MA-G is an employee and shareholder of Paratek Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Both\u00a0authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}